Modifications of p53: competing for the lysines

Current Opinion in Genetics and Development

Volumn 19, Issue 1, 2009, Pages 18-24

  Carter, Stephanie ^a   Vousden, Karen H ^a  

^a BEATSON INSTITUTE FOR CANCER RESEARCH   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

LYSINE; PROTEIN P53; SERINE; THREONINE;

ACETYLATION; APOPTOSIS; CELLULAR DISTRIBUTION; CYTOPLASM; HUMAN; METHYLATION; PHOSPHORYLATION; PRIORITY JOURNAL; PROTEIN LOCALIZATION; REVIEW;

ANIMALS; HUMANS; LYSINE; MODELS, BIOLOGICAL; PROTEIN PROCESSING, POST-TRANSLATIONAL; PROTEIN STRUCTURE, TERTIARY; TUMOR SUPPRESSOR PROTEIN P53;

EID: 61449190667     PISSN: 0959437X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.gde.2008.11.010     Document Type: Review

References (59)

1. Olsson A., Manzl C., Strasser A., and Villunger A. How important are post-translational modifications in p53 for selectivity in target-gene transcription and tumour suppression?. Cell Death Differ 14 (2007) 1561-1575
2. Kruse J.P., and Gu W. SnapShot: p53 posttranslational modifications. Cell 133 (2008) 930-931
3. Horn H.F., and Vousden K.H. Coping with stress: multiple ways to activate p53. Oncogene 26 (2007) 1306-1316
4. Montes de Oca Luna R., Wagner D.S., and Lozano G. Rescue of early embryonic lethality in mdm2-deficient mice by deletion of p53. Nature 378 (1995) 203-206
5. Ringshausen I., O'Shea C.C., Finch A.J., Swigart L.B., and Evan G.I. Mdm2 is critically and continuously required to suppress lethal p53 activity in vivo. Cancer Cell 10 (2006) 501-514
6. Feng L., Lin T., Uranishi H., Gu W., and Xu Y. Functional analysis of the roles of posttranslational modifications at the p53 C terminus in regulating p53 stability and activity. Mol Cell Biol 25 (2005) 5389-5395
7. Krummel K.A., Lee C.J., Toledo F., and Wahl G.M. The C-terminal lysines fine-tune p53 stress response in a mouse model but are not required for stability control or transactivation. Proc Natl Acad Sci U S A 102 (2005) 10188-10193
8. Li M., Brooks C.L., Wu-Baer F., Chen D., Baer R., and Gu W. Mono- versus polyubiquitination: differential control of p53 fate by Mdm2. Science 302 (2003) 1972-1975
9. Nie L., Sasaki M., and Maki C.G. Regulation of p53 nuclear export through sequential changes in conformation and ubiquitination. J Biol Chem 282 (2007) 14616-14625
10. Laine A., Topisirovic I., Zhai D., Reed J.C., Borden K.L., and Ronai Z. Regulation of p53 localization and activity by Ubc13. Mol Cell Biol 26 (2006) 8901-8913
11. Moll U.M., Wolff S., Speidel D., and Deppert W. Transcription-independent pro-apoptotic functions of p53. Curr Opin Cell Biol 17 (2005) 631-636
12. Tasdemir E., Maiuri M.C., Galluzzi L., Vitale I., Djavaheri-Mergny M., D'Amelio M., Criollo A., Morselli E., Zhu C., Harper F., et al. Regulation of autophagy by cytoplasmic p53. Nat Cell Biol 10 (2008) 676-687. The first paper describing an entirely unexpected effect of cytoplasmic p53 in the inhibition of autohagy. These results underscore the complexity of the effect of p53 on autophagy, since several transcriptional targets of p53 have been shown to enhance autophagy.
13. Carter S., and Vousden K.H. p53-Ubl fusions as models of ubiquitination, sumolyation and neddylation of p53. Cell Cycle 7 (2008) 2519-2528
14. Marchenko N.D., Wolff S., Erster S., Becker K., and Moll U.M. Monoubiquitylation promotes mitochondrial p53 translocation. EMBO J 26 (2007) 923-934
15. Le Cam L., Linares L.K., Paul C., Julien E., Lacroix M., Hatchi E., Triboulet R., Bossis G., Shmueli A., Rodriguez M.S., et al. E4F1 is an atypical ubiquitin ligase that modulates p53 effector functions independently of degradation. Cell 127 (2006) 775-788. While the effect of most ubiquitin ligases for p53 is to target the protein for degradation, this paper describes E4F1 as a modulator of p53 function, by ubiquitinating a lysine normally acetylated by PCAF.
16. Brooks C.L., Li M., and Gu W. Mechanistic studies of MDM2-mediated ubiquitination in p53 regulation. J Biol Chem 282 (2007) 22804-22815
17. Grossman S.R., Deato M.E., Brignone C., Chan H.M., Kung A.L., Tagami H., Nakatani Y., and Livingston D.M. Polyubiquitination of p53 by a ubiquitin ligase activity of p300. Science 300 (2003) 342-344
18. Sui G., Affar el B., Shi Y., Brignone C., Wall N.R., Yin P., Donohoe M., Luke M.P., Calvo D., Grossman S.R., et al. Yin Yang 1 is a negative regulator of p53. Cell 117 (2004) 859-872
19. Higashitsuji H., Higashitsuji H., Itoh K., Sakurai T., Nagao T., Sumitomo Y., Masuda T., Dawson S., Shimada Y., Mayer R.J., et al. The oncoprotein gankyrin binds to MDM2/HDM2, enhancing ubiquitylation and degradation of p53. Cancer Cell 8 (2005) 75-87
20. Carter S., Bischof O., Dejean A., and Vousden K.H. C-terminal modifications regulate MDM2 dissociation and nuclear export of p53. Nat Cell Biol 9 (2007) 428-435. This study revealed the complex interplay between different Ubl modifications of p53, and showed that these result in the release of MDM2, a necessary event for nuclear export of the p53 protein.
21. Tang Y., Zhao W., Chen Y., Zhao Y., and Gu W. Acetylation is indispensable for p53 activation. Cell 133 (2008) 612-626. Although up to seven acetylation sites had been mutated in previous studies, with relatively subtle effects on p53 function, this paper showed that simultaneous mutation of eight acetylation sites completely abolished the ability of p53 to induce cell cycle arrest or apoptosis.
22. Oliner J.D., Pietenpol J.A., Thiagalingam S., Gyuris J., Kinzler K.W., and Vogelstein B. Oncoprotein MDM2 conceals the activation domain of tumour suppressor p53. Nature 362 (1993) 857-860
23. Kobet E., Zeng X., Zhu Y., Keller D., and Lu H. MDM2 inhibits p300-mediated p53 acetylation and activation by forming a ternary complex with the two proteins. Proc Natl Acad Sci U S A 97 (2000) 12547-12552
24. Ito A., Kawaguchi Y., Lai C.H., Kovacs J.J., Higashimoto Y., Appella E., and Yao T.P. MDM2-HDAC1-mediated deacetylation of p53 is required for its degradation. EMBO J 21 (2002) 6236-6245
25. Itahana K., Mao H., Jin A., Itahana Y., Clegg H.V., Lindstrom M.S., Bhat K.P., Godfrey V.L., Evan G.I., and Zhang Y. Targeted inactivation of Mdm2 RING finger E3 ubiquitin ligase activity in the mouse reveals mechanistic insights into p53 regulation. Cancer Cell 12 (2007) 355-366. An extremely interesting in vivo study showing that the ubiquitin ligase activity of MDM2 is absolutely essential for the regulation of p53. Intriguingly, the paper also suggests that MDM2's autoubiquitination activity is not necessary for the rapid turnover of MDM2 itself - implying the existence of another ubiquitin ligase that can target MDM2 for degradation.
26. Marine J.C., Francoz S., Maetens M., Wahl G., Toledo F., and Lozano G. Keeping p53 in check: essential and synergistic functions of Mdm2 and Mdm4. Cell Death Differ 13 (2006) 927-934
27. Kahyo T., Nishida T., and Yasuda H. Involvement of PIAS1 in the sumoylation of tumor suppressor p53. Mol Cell 8 (2001) 713-718
28. Schmidt D., and Muller S. Members of the PIAS family act as SUMO ligases for c-Jun and p53 and repress p53 activity. Proc Natl Acad Sci U S A 99 (2002) 2872-2877
29. Bischof O., Schwamborn K., Martin N., Werner A., Sustman C., Grosschedl R., and Dejean A. The E3 SUMO ligase PIASy is a novel regulator of cellular senscence and apoptosis. Mol Cell 22 (2006) 783-794. Although the effect of SUMOylation on p53 activity is not completely clear, this study provides some intriguing evidence that SUMOylation of p53 may help to drive the senescence response.
30. Weger S., Hammer E., and Heilbronn R. Topors acts as a SUMO-1 E3 ligase for p53 in vitro and in vivo. FEBS Lett 579 (2005) 5007-5012
31. Chen L., and Chen J. MDM2-ARF complex regulates p53 sumoylation. Oncogene 22 (2003) 5348-5357
32. Melchior F., and Hengst L. SUMO-1 and p53. Cell Cycle 1 (2002) 245-249
33. Pichler A., and Melchior F. Ubiquitin-related modifier SUMO1 and nucleocytoplasmic transport. Traffic 3 (2002) 381-387
34. •], this study shows a correlation between p53 modification by SUMO and the induction of cellular senescence.
35. Xirodimas D.P., Saville M.K., Bourdon J.C., Hay R.T., and Lane D.P. Mdm2-mediated NEDD8 conjugation of p53 inhibits its transcriptional activity. Cell 118 (2004) 83-97
36. Abida W.M., Nikolaev A., Zhao W., Zhang W., and Gu W. FBXO11 promotes the Neddylation of p53 and inhibits its transcriptional activity. J Biol Chem 282 (2007) 1797-1804. The first identifcation of FBXO11 as a p53-interacting protein that promoted the Neddylation of p53, with a resultant inhibition of p53 function.
37. Grossman S.R. p300/CBP/p53 interaction and regulation of the p53 response. Eur J Biochem 268 (2001) 2773-2778
38. Wang Y.H., Tsay Y.G., Tan B.C., Lo W.Y., and Lee S.C. Identification and characterization of a novel p300-mediated p53 acetylation site, lysine 305. J Biol Chem 278 (2003) 25568-25576
39. Sakaguchi K., Herrera J.E., Saito S., Miki T., Bustin M., Vassilev A., Anderson C.W., and Appella E. DNA damage activates p53 through a phosphorylation-acetylation cascade. Genes Dev 12 (1998) 2831-2841
40. Knights C.D., Catania J., Di Giovanni S., Muratoglu S., Perez R., Swartzbeck A., Quong A.A., Zhang X., Beerman T., Pestell R.G., et al. Distinct p53 acetylation cassettes differentially influence gene-expression patterns and cell fate. J Cell Biol 173 (2006) 533-544
41. Tang Y., Luo J., Zhang W., and Gu W. Tip60-dependent acetylation of p53 modulates the decision between cell-cycle arrest and apoptosis. Mol Cell 24 (2006) 827-839
42. Sykes S.M., Mellert H.S., Holbert M.A., Li K., Marmorstein R., Lane W.S., and McMahon S.B. Acetylation of the p53 DNA-binding domain regulates apoptosis induction. Mol Cell 24 (2006) 841-851
43. Huang J., and Berger S.L. The emerging field of dynamic lysine methylation of non-histone proteins. Curr Opin Genet Dev 18 (2008) 152-158
44. Chuikov S., Kurash J.K., Wilson J.R., Xiao B., Justin N., Ivanov G.S., McKinney K., Tempst P., Prives C., Gamblin S.J., et al. Regulation of p53 activity through lysine methylation. Nature 432 (2004) 353-360
45. Huang J., Perez-Burgos L., Placek B.J., Sengupta R., Richter M., Dorsey J.A., Kubicek S., Opravil S., Jenuwein T., and Berger S.L. Repression of p53 activity by Smyd2-mediated methylation. Nature 444 (2006) 629-632
46. Shi X., Kachirskaia I., Yamaguchi H., West L.E., Wen H., Wang E.W., Dutta S., Appella E., and Gozani O. Modulation of p53 function by SET8-mediated methylation at lysine 382. Mol Cell 27 (2007) 636-646
47. Huang J., Sengupta R., Espejo A.B., Lee M.G., Dorsey J.A., Richter M., Opravil S., Shiekhattar R., Bedford M.T., Jenuwein T., et al. p53 is regulated by the lysine demethylase LSD1. Nature 449 (2007) 105-108. A study that identifies a demethylase of p53 that can selectively reverse dimethylation and so affect the interaction of p53 with the coactivator 53BP1.
48. •], this study shows that methylation of p53 can result in the recognition of the protein by the tudor domain of 53BP1.
49. Dohmesen C., Koeppel M., and Dobbelstein M. Specific inhibition of Mdm2-mediated neddylation by Tip60. Cell Cycle 7 (2008) 222-231
50. ••]
51. ••] shows that the methylation of p53 by Set7/9 forms a binding site for the acetyltransferase Tip60,elegantly revealing the link between methylation and acetylation.
52. Li M., Brooks C.L., Kon N., and Gu W. A dynamic role of HAUSP in the p53-Mdm2 pathway. Mol Cell 13 (2004) 879-886
53. •], this paper demonstrates that repression of the enzymes that remove SUMO can enhance senescence by inducing p53 activity.
54. Dey A., Verma C.S., and Lane D.P. Updates on p53: modulation of p53 degradation as a therapeutic approach. Br J Cancer 98 (2008) 4-8
55. Lain S., Hollick J.J., Campbell J., Staples O.D., Higgins M., Aoubala M., McCarthy A., Appleyard V., Murray K.E., Baker L., et al. Discovery, in vivo activity, and mechanism of action of a small-molecule p53 activator. Cancer Cell 13 (2008) 454-463. A phenotypic screen for small molecule activators of p53, with elegant deconvolution using a yeast genetic screen to identify the mechanism of function of the identified compounds as inhibitors of the deacetylating enzymes SirT1 and SirT2.
56. Langley E., Pearson M., Faretta M., Bauer U.M., Frye R.A., Minucci S., Pelicci P.G., and Kouzarides T. Human SIR2 deacetylates p53 and antagonizes PML/p53-induced cellular senescence. EMBO J 21 (2002) 2383-2396
57. Vaziri H., Dessain S.K., Ng Eaton E., Imai S.I., Frye R.A., Pandita T.K., Guarente L., and Weinberg R.A. hSIR2(SIRT1) functions as an NAD-dependent p53 deacetylase. Cell 107 (2001) 149-159
58. Cheng H.L., Mostoslavsky R., Saito S., Manis J.P., Gu Y., Patel P., Bronson R., Appella E., Alt F.W., and Chua K.F. Developmental defects and p53 hyperacetylation in Sir2 homolog (SIRT1)-deficient mice. Proc Natl Acad Sci U S A 100 (2003) 10794-10799
59. Costanzo A., Merlo P., Pediconi N., Fulco M., Sartorelli V., Cole P.A., Fontemaggi G., Fanciulli M., Schiltz L., Blandino G., et al. DNA damage-dependent acetylation of p73 dictates the selective activation of apoptotic target genes. Mol Cell 9 (2002) 175-186